Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL)
administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in
patients with refractory partial epilepsy over a 12-week maintenance period.